Form 8-K - Current report:
SEC Accession No. 0001214659-22-012061
Filing Date
2022-10-05
Accepted
2022-10-05 16:30:28
Documents
14
Period of Report
2022-10-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 b1052208k.htm   iXBRL 8-K 26748
2 EXHIBIT 99.1 ex99_1.htm EX-99.1 9996
6 GRAPHIC alzamendlogo_sm.jpg GRAPHIC 18173
  Complete submission text file 0001214659-22-012061.txt   240330

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE alzn-20221005_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE alzn-20221005_pre.xml EX-101.PRE 22343
5 XBRL SCHEMA FILE alzn-20221005.xsd EX-101.SCH 3203
8 EXTRACTED XBRL INSTANCE DOCUMENT b1052208k_htm.xml XML 3702
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 221295984
SIC: 2834 Pharmaceutical Preparations